- Home
- IHS vs HTFL Comparison
IHS vs HTFL Comparison
Compare IHS & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IHS | HTFL |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | IHS | HTFL |
|---|---|---|
| Price | $7.26 | $30.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $9.32 | ★ $39.50 |
| AVG Volume (30 Days) | ★ 980.1K | 738.8K |
| Earning Date | 11-12-2025 | 02-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $1,765,825,000.00 | $161,881,000.00 |
| Revenue This Year | $3.49 | $40.42 |
| Revenue Next Year | $2.77 | $22.27 |
| P/E Ratio | $5.30 | ★ N/A |
| Revenue Growth | N/A | ★ 85.70 |
| 52 Week Low | $2.90 | $25.38 |
| 52 Week High | $8.00 | $41.22 |
Technical Indicators
Market Signals| Indicator | IHS | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | N/A |
| Support Level | $7.08 | N/A |
| Resistance Level | $7.53 | N/A |
| Average True Range (ATR) | 0.23 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 19.77 | 0.00 |
Price Performance
Historical ComparisonAbout IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.